Aptargroup Inc (ATR)
Juste valeurFondamental
66
Prix
$121.16
Capitalisation boursière
$7.91B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
It supplies the elastomeric stoppers, seals and injection delivery systems that compete head-on with Aptar Pharma's injectables business for the same drug makers.
Through Silgan Dispensing Systems it makes the same pumps, trigger sprayers and dispensing closures Aptar sells to beauty, home care and food and beverage brands.
This French maker of nasal sprays, preservative-free eyedroppers and inhalers bids for the same drug-delivery device contracts with pharmaceutical companies as Aptar Pharma.
The German group sells inhalers, pen injectors and primary pharmaceutical packaging, and also cosmetics packaging, to the same pharma and beauty customers Aptar serves in Europe and the United States.
After absorbing Berry Global in April 2025 it is a large supplier of closures, dispensing components and healthcare packaging to the consumer and pharmaceutical brands Aptar depends on.
The privately held German closure specialist competes with Aptar's Food + Beverage segment on dispensing and non-dispensing plastic caps for drinks, edible oils and household liquids.
Bilan & Liquidités
Chiffre d'affaires
$3.93B
12 derniers mois (au 30/06/2026)
Résultat net
$363M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$300M
Capitaux propres totaux
$2.67B
Passif total
$2.57B
Ratio de liquidité général
1.61
Couverture des intérêts
7.52
Dette/EBITDA
1.79
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$154.38
Prix actuel
$121.16
Marge de sécurité
+21.5%
Fourchette de juste valeur
$116.80 - $191.96
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
21.91
ROE
14.7%
Ratio P/B
2.93
P/FCF
24.82
Marge brute
-
ROIC
9.4%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
9.4%
WACC
7.2%
ROIC − WACC
+2.2 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (21)
- EPS shows upward trend
- EPS CAGR 6.02%
- Price CAGR 5.45%
- ROIC 9.4%
- P/FCF 24.82
- P/B Ratio 2.93
- Debt/Equity ratio
- Operating Margin 12.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 13.6%
- Revenue Growth 5Y 5.2%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 4.0%
- PEG Ratio 1.66
- Earnings Quality (OCF/NI) 1.61
- Share Dilution -1.5%
- Piotroski F-Score 5/9
Échoué (5)
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Net Margin Trend 9.2% vs 10.8%
Indisponible (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Aucune déclaration institutionnelle pour cette entreprise.
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Gael Touya | CEO, President & Director | 55 |
| Ms. Vanessa Kanu | Executive VP & CFO | 47 |
| Mr. Stephan B. Tanda | Director & Advisor | 60 |
| Mr. Marc Prieur | President of Aptar Beauty | 59 |
| Ms. Xiangwei Gong | Executive VP of Strategic Group Development & President of Aptar Asia | 55 |
| Mr. Hedi Tlili | President of Aptar Closures | 50 |
| Mr. Aditya J. Gandhi | VP, Principal Accounting Officer & Chief Accounting Officer | 45 |
| Ms. Mary Skafidas | Senior Vice President of Investor Relations & Communications | - |
| Ms. Irene Hudson | Executive VP, Chief Legal Officer & Corporate Secretary | 48 |
| Ms. Shiela Pallerne Vinczeller | Chief Human Resources Officer | 61 |
Risque d'audit
1
Risque du conseil
1
Risque de rémunération
2
Risque droits des actionnaires
5
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-06
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-31
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-21
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for ATR, sourced from Markets Gazette.
- 28d agoPOSITIVEATR (JV Leonardo-Airbus), maxi ordine da 1 miliardo di dollari dall'indiana FLY91
Indian regional airline FLY91 has placed a landmark order for 40 ATR 72-600 aircraft, valued at approximately $1 billion. This significant deal represents the largest order for ATR globally from a single airline. The ATR 72-600 is a turboprop regional airliner, and this order underscores FLY91's commitment to expanding its regional network. For investors in Leonardo (a partner in the ATR joint venture), this order signals strong demand for regional aircraft and a positive outlook for the turboprop market, potentially boosting future revenues and profitability.
- 2/28/2026POSITIVERiver Road Loads Up on ATR With 917,000 Shares in New Position
River Road, a prominent investment manager, has announced the establishment of a new significant position in AptarGroup Inc., acquiring 917,000 shares. AptarGroup is a global provider of proprietary dispensing and sealing solutions for the healthcare, beauty, and consumer markets. This strategic move by River Road signals strong confidence in AptarGroup's future prospects, suggesting the company may be undervalued or poised for significant growth. Investors might interpret this as a bullish signal, indicating potential increased interest and demand for ATR shares, given its robust global market positioning.
via Markets Gazette